Advertisement

Topics

Moderna Announces First-in-Human Dosing for Phase 1 Study (KEYNOTE-603) of mRNA-4157, a ...

04:06 EST 15 Nov 2017 | BioMedReports - Blog

--Moderna and Merck collaborating to evaluate mRNA-4157 in combination with KEYTRUDA® (pembrolizumab)--

Read more...

Original Article: Moderna Announces First-in-Human Dosing for Phase 1 Study (KEYNOTE-603) of mRNA-4157, a ...

NEXT ARTICLE

More From BioPortfolio on "Moderna Announces First-in-Human Dosing for Phase 1 Study (KEYNOTE-603) of mRNA-4157, a ..."

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...